This review summarizes the pathophysiology, classification, and treatment of von Willebrand disease, highlighting desmopressin as the primary treatment for type 1 vWD.
Answers are grounded in this paper and cite their sources.
Supports desmopressin preference in type 1 vWD; leaves open prospective validation of concentrate strategies in nonresponders.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Budde et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: